Catalyst Wire Dossier Catalyst Wire Dossier

MK-1484

· Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-1484, covering 2024-11-14 to 2024-11-14. Get the full timeline:

Most recent: Clinical Trial Update: A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) [Phase 1]

See pricing